Drug Profile
Darvadstrocel - TiGenix
Alternative Names: Alofisel; Cx-601Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cellerix
- Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; Takeda; TiGenix
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rectal fistula
- No development reported Rectovaginal fistula; Ulcerative colitis
Most Recent Events
- 17 Oct 2023 Adverse events data from the phase III ADMIRE-CD II trial in Crohn's disease released by Takeda
- 30 Jun 2023 Discontinued - Phase-III for Rectal fistula in USA (Intralesional) (Takeda pipeline; February 2024)
- 10 Feb 2023 Takeda completes a phase-III clinical trials in Rectal fistula in Japan (Intralesional) (NCT03706456)